LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular is a well-established company with a proven track record of success. They have a strong and diversified portfolio of products that are well-known and widely used by vascular surgeons globally. The company has consistently delivered double-digit organic revenue growth and has a healthy balance sheet with significant cash reserves. The recent increase in their EPS guidance for FY/26, along with their plans for continued international expansion and potential M&A activity, further solidify our positive outlook on the company.

LeMaitre Vascular is maintaining its FY/26 revenue guidance at 12%, but with an increased adjusted EPS range and a continuing improvement in gross margin, the company appears to be gaining confidence in its profitability forecast for the year. Additionally, the top-line growth is being driven by key products such as grafts, valvulotomes, and carotid shunts, with strong performance in international markets. The company's guidance for next quarter also shows significant growth in revenue, gross margin, operating income, and EPS, but management noted that the second half of the year may have higher operating expenses due to investments in Artegraft, warehousing, manufacturing, and sales force.